Rinkey Investments Salarius Pharmaceuticals, Inc. Transaction History

Rinkey Investments

  • $307 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 09, 2022
SELL
$0.34 - $0.54 $34 - $54
-100 Closed
0 $0
Q4 2021

Feb 17, 2022
BUY
$0.49 - $1.01 $49 - $101
100 New
100 $0

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $3.32M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Rinkey Investments Portfolio

Follow Rinkey Investments and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rinkey Investments, based on Form 13F filings with the SEC.

News

Stay updated on Rinkey Investments with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email